Literature DB >> 34626665

Ibudilast attenuates cocaine self-administration and prime- and cue-induced reinstatement of cocaine seeking in rats.

Lianwei Mu1, Xiaojie Liu1, Hao Yu2, Mengming Hu1, Vladislav Friedman1, Thomas J Kelly1, Li Zhao3, Qing-Song Liu4.   

Abstract

Ibudilast is a non-selective phosphodiesterase (PDE) inhibitor and glial cell modulator which has shown great promise for the treatment of drug and alcohol use disorders in recent clinical studies. However, it is unknown whether and how ibudilast affects cocaine seeking behavior. Here we show that systemic administration of ibudilast dose-dependently reduced cocaine self-administration under fixed- and progressive-ratio reinforcement schedules in rats and shifted cocaine dose-response curves downward. In addition, ibudilast decreased cocaine prime- and cue-induced reinstatement of cocaine seeking. These results indicate that ibudilast was effective in reducing the reinforcing effects of cocaine and relapse to cocaine seeking. Chronic cocaine exposure induces cAMP-related neuroadaptations in the reward circuitry of the brain. To investigate potential mechanisms for ibudilast-induced attenuation of cocaine self-administration, we recorded from ventral tegmental area (VTA) dopamine neurons in ex vivo midbrain slices prepared from rats that had undergone saline and cocaine self-administration. We found cocaine self-administration led to a decrease in inhibitory postsynaptic currents (IPSCs), an increase in the AMPAR/NMDAR ratio, and an increase in the excitation to inhibition (E/I) ratio. Ibudilast pretreatments enhanced GABAergic inhibition and did not further change cocaine-induced potentiation of excitation, leading to normalization of the E/I ratio. Restoration of the balance between excitation and inhibition in VTA dopamine neurons may contribute to the attenuation of cocaine self-administration by ibudilast.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cocaine; Ibudilast; Reinstatement; Self-administration; Synaptic plasticity; Ventral tegmental area

Mesh:

Substances:

Year:  2021        PMID: 34626665      PMCID: PMC8656241          DOI: 10.1016/j.neuropharm.2021.108830

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  69 in total

1.  The glial cell modulators, ibudilast and its amino analog, AV1013, attenuate methamphetamine locomotor activity and its sensitization in mice.

Authors:  Sarah E Snider; Sarah A Vunck; Edwin J C G van den Oord; Daniel E Adkins; Joseph L McClay; Patrick M Beardsley
Journal:  Eur J Pharmacol       Date:  2012-01-28       Impact factor: 4.432

Review 2.  A critique of fixed and progressive ratio schedules used to examine the neural substrates of drug reinforcement.

Authors:  J M Arnold; D C Roberts
Journal:  Pharmacol Biochem Behav       Date:  1997-07       Impact factor: 3.533

3.  Control of GluR1 AMPA receptor function by cAMP-dependent protein kinase.

Authors:  T G Banke; D Bowie; H Lee; R L Huganir; A Schousboe; S F Traynelis
Journal:  J Neurosci       Date:  2000-01-01       Impact factor: 6.167

Review 4.  Glial modulators as potential treatments of psychostimulant abuse.

Authors:  Patrick M Beardsley; Kurt F Hauser
Journal:  Adv Pharmacol       Date:  2014

5.  Distinct cellular properties of identified dopaminergic and GABAergic neurons in the mouse ventral tegmental area.

Authors:  Billy Chieng; Yael Azriel; Sarasa Mohammadi; MacDonald J Christie
Journal:  J Physiol       Date:  2011-06-06       Impact factor: 5.182

6.  The glial cell modulator and phosphodiesterase inhibitor, AV411 (ibudilast), attenuates prime- and stress-induced methamphetamine relapse.

Authors:  Patrick M Beardsley; Keith L Shelton; Elizabeth Hendrick; Kirk W Johnson
Journal:  Eur J Pharmacol       Date:  2010-04-23       Impact factor: 4.432

7.  BDNF regulates the maturation of inhibition and the critical period of plasticity in mouse visual cortex.

Authors:  Z J Huang; A Kirkwood; T Pizzorusso; V Porciatti; B Morales; M F Bear; L Maffei; S Tonegawa
Journal:  Cell       Date:  1999-09-17       Impact factor: 41.582

8.  CTDP-32476: A Promising Agonist Therapy for Treatment of Cocaine Addiction.

Authors:  Zheng-Xiong Xi; Rui Song; Xia Li; Guan-Yi Lu; Xiao-Qing Peng; Yi He; Guo-Hua Bi; Siyuan Peter Sheng; Hong-Ju Yang; Haiying Zhang; Jin Li; Mark Froimowitz; Eliot L Gardner
Journal:  Neuropsychopharmacology       Date:  2016-08-18       Impact factor: 7.853

9.  Ibudilast reduces alcohol drinking in multiple animal models of alcohol dependence.

Authors:  Richard L Bell; Marcelo F Lopez; Changhai Cui; Mark Egli; Kirk W Johnson; Kelle M Franklin; Howard C Becker
Journal:  Addict Biol       Date:  2013-11-11       Impact factor: 4.280

10.  Ibudilast, a neuroimmune modulator, reduces heavy drinking and alcohol cue-elicited neural activation: a randomized trial.

Authors:  Erica N Grodin; Spencer Bujarski; Brandon Towns; Elizabeth Burnette; Steven Nieto; Aaron Lim; Johnny Lin; Karen Miotto; Artha Gillis; Michael R Irwin; Christopher Evans; Lara A Ray
Journal:  Transl Psychiatry       Date:  2021-06-12       Impact factor: 6.222

View more
  2 in total

1.  Integrated Excitatory/Inhibitory Imbalance and Transcriptomic Analysis Reveals the Association between Dysregulated Synaptic Genes and Anesthetic-Induced Cognitive Dysfunction.

Authors:  Yasheng Yan; Sarah Logan; Xiaojie Liu; Bixuan Chen; Congshan Jiang; Thiago Arzua; Ramani Ramchandran; Qing-Song Liu; Xiaowen Bai
Journal:  Cells       Date:  2022-08-11       Impact factor: 7.666

2.  Epac2 in midbrain dopamine neurons contributes to cocaine reinforcement via enhancement of dopamine release.

Authors:  Xiaojie Liu; Casey R Vickstrom; Hao Yu; Shuai Liu; Shana Terai Snarrenberg; Vladislav Friedman; Lianwei Mu; Bixuan Chen; Thomas J Kelly; David A Baker; Qing-Song Liu
Journal:  Elife       Date:  2022-08-22       Impact factor: 8.713

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.